专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210137838A1 LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY 有权
公开(公告)号：US20210137838A1
公开(公告)日：2021-05-13
申请号：US16491834
申请日：2018-03-13
申请人： SDG, Inc.
发明人： W. Blair Geho
IPC分类号： A61K9/127 , A61K47/69 , A61K38/28 , A61P3/10
摘要： The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.

2. 发明授权

US09034372B2 Lipid construct for delivery of insulin to a mammal 有权
标题翻译：用于向哺乳动物递送胰岛素的脂质构建体
公开(公告)号：US09034372B2
公开(公告)日：2015-05-19
申请号：US14511743
申请日：2014-10-10
申请人： SDG, Inc.
发明人： John R. Lau , W. Blair Geho
IPC分类号： A61K9/127 , A61K38/38 , A61K38/28 , A61K47/14 , A61K47/24 , A61K47/28
CPC分类号： A61K9/1271 , A61K9/1272 , A61K38/28 , A61K47/14 , A61K47/24 , A61K47/28
摘要： The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.
摘要翻译：本发明涉及一种肝细胞靶向组合物，其包含与脂质构建体相关的胰岛素，所述脂质构建体包含两亲性脂质和将构建体靶向由肝细胞显示的受体的扩展两亲性脂质。组合物可以包含与复合物相关的游离胰岛素和胰岛素的混合物。可以修饰组合物以保护胰岛素和复合物免于降解。本发明还包括用于制备组合物并将胰岛素装载到组合物中并回收组合物的各种组分的方法。治疗糖尿病患者的方法

3. 发明申请

US20090087479A1 Orally bioavailable lipid-based constructs 有权
标题翻译：口服生物可利用的基于脂质的构建体
公开(公告)号：US20090087479A1
公开(公告)日：2009-04-02
申请号：US11904937
申请日：2007-09-28
申请人： John R. Lau , W. Blair Geho
发明人： John R. Lau , W. Blair Geho
IPC分类号： A61K9/127 , A61K38/28 , A61P3/00
CPC分类号： A61K9/127 , A61K9/1277 , A61K31/4045 , A61K38/21 , A61K38/23 , A61K38/28 , A61K47/24
摘要： The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetucic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
摘要翻译：本发明通过能够通过消化道的环境与典型的非口服可用的治疗剂或诊断剂分娩使得治疗药物或诊断剂是生物可利用的组合物来实现的。组合物可以或不可以靶向特定的细胞受体，例如肝细胞。治疗剂包括但不限于胰岛素，降钙素，5-羟色胺和其它蛋白质。用生物素或金属靶向剂完成靶向。

4. 发明申请

US20060222698A1 Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal 有权
标题翻译：用于向哺乳动物递送甘精胰岛素的肝细胞递送载体
公开(公告)号：US20060222698A1
公开(公告)日：2006-10-05
申请号：US11384728
申请日：2006-03-20
申请人： John Lau , W. Geho
发明人： John Lau , W. Geho
IPC分类号： A61K38/28 , A61K9/127
CPC分类号： A61K9/1271 , A61K38/28
摘要： The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free glargine insulin and glargine insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Glargine insulin is present within the complex in at least one form wherein the glargine insulin has a positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.
摘要翻译：本发明涉及包含与水不溶性靶分子复合物相关的甘精胰岛素和甘精胰岛素的混合物的肝细胞靶向组合物，其中所述复合物包含多个连接的单个单元和超分子脂质构建体基质。甘精胰岛素以至少一种形式存在于复合物内，其中甘精胰岛素具有与复合物上的负电荷相互作用的正电荷。本发明还包括用于制备I型和II型糖尿病个体的血糖水平组合物和方法的方法。

5. 发明授权

US07871641B2 Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal 有权
标题翻译：用于向哺乳动物递送甘精胰岛素的肝细胞靶向载体
公开(公告)号：US07871641B2
公开(公告)日：2011-01-18
申请号：US11384728
申请日：2006-03-20
申请人： John R. Lau , W. Blair Geho
发明人： John R. Lau , W. Blair Geho
IPC分类号： A61K9/127
CPC分类号： A61K9/1271 , A61K38/28
摘要： The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free glargine insulin and glargine insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Glargine insulin is present within the complex in at least one form wherein the glargine insulin has a positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.
摘要翻译：本发明涉及包含与水不溶性靶分子复合物相关的甘精胰岛素和甘精胰岛素的混合物的肝细胞靶向组合物，其中所述复合物包含多个连接的单个单元和超分子脂质构建体基质。甘精胰岛素以至少一种形式存在于复合物内，其中甘精胰岛素具有与复合物上的负电荷相互作用的正电荷。本发明还包括用于制备I型和II型糖尿病个体的血糖水平组合物和方法的方法。

6. 发明申请

US20100247625A1 Orally Bioavailable Lipid-Based Constructs 有权
标题翻译：口腔生物可利用的脂质结构
公开(公告)号：US20100247625A1
公开(公告)日：2010-09-30
申请号：US12732952
申请日：2010-03-26
申请人： W. Blair Geho , John R. Lau
发明人： W. Blair Geho , John R. Lau
IPC分类号： A61K9/127 , A61P3/04 , A61P3/02 , A61K38/28 , A61K31/4188 , A61K39/44 , A61K31/4045 , A61K38/23 , A61P5/22 , A61K38/26 , A61K31/198 , A61K38/21 , A61P3/10 , A61P31/14 , A61P3/06 , A23L1/303
CPC分类号： C07K16/00 , A23L33/10 , A23L33/15 , A23L33/17 , A61K9/1272 , A61K9/4858 , A61K31/198 , A61K31/4045 , A61K31/4188 , A61K38/39 , A61K47/544 , A61K2039/505 , A61K2039/542 , A61K2300/00
摘要： The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
摘要翻译：本发明通过能够在有需要的患者中引起体重减轻的组合物来实现。

7. 发明申请

US20070218117A1 Supra molecular construct for delivery of interferon to a mammal 审中-公开
标题翻译：用于向哺乳动物递送干扰素的分子构建体
公开(公告)号：US20070218117A1
公开(公告)日：2007-09-20
申请号：US11384575
申请日：2006-03-20
申请人： John Lau , W. Geho
发明人： John Lau , W. Geho
IPC分类号： A61K38/21 , A61K9/127 , A61K31/717
CPC分类号： A61K9/0014 , A61K9/1075 , A61K31/717 , A61K38/212 , A61K47/24 , A61K47/544
摘要： The instant invention is drawn to a hepatocyte targeted composition comprising interferon associated with a supra-molecular lipid construct comprising amphipathic lipid molecules and receptor binding molecule. The composition can comprise a mixture of free interferon and interferon associated with the complex. The composition can be modified to protect interferon and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading interferon into the composition and recycling various components of the composition. Methods of treating individuals infected with the hepatitis C and other hepatitis viruses.
摘要翻译：本发明涉及包含与包含两亲性脂质分子和受体结合分子的超分子脂质构建体相关的干扰素的肝细胞靶向组合物。组合物可以包含与复合物相关的游离干扰素和干扰素的混合物。可以修饰组合物以保护干扰素和复合物免于降解。本发明还包括用于制造组合物并将干扰素加载到组合物中并回收组合物的各种组分的方法。治疗丙型肝炎及其他肝炎病毒感染个体的方法。

8. 发明申请

US20220110870A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL 有权
公开(公告)号：US20220110870A1
公开(公告)日：2022-04-14
申请号：US17230089
申请日：2021-04-14
申请人： SDG, INC.
发明人： JOHN R. LAU , W. BLAIR GEHO
IPC分类号： A61K9/127 , A61K38/28 , A61K47/14 , A61K47/24 , A61K47/28
摘要： The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

9. 发明授权

US11071715B2 Lipid-based nanoparticles and methods using same 有权
公开(公告)号：US11071715B2
公开(公告)日：2021-07-27
申请号：US16563119
申请日：2019-09-06
申请人： SDG, Inc.
发明人： W. Blair Geho
IPC分类号： A61K38/28 , A61K9/51 , A61K47/69 , A61P3/10 , A61K9/127
摘要： The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.

10. 发明授权

US10568835B2 Orally bioavailable lipid-based constructs 有权
公开(公告)号：US10568835B2
公开(公告)日：2020-02-25
申请号：US14592205
申请日：2015-01-08
申请人： SDG, INC.
发明人： John R. Lau , W. Blair Geho
IPC分类号： A61K9/127 , A61K38/28 , A61K38/23 , A61K31/4045 , A61K38/21 , A61K47/24
摘要： The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式